1.Noncardiac Chest Pain: Update on the Diagnosis and Management.
Yang Won MIN ; Poong Lyul RHEE
The Korean Journal of Gastroenterology 2015;65(2):76-84
Noncardiac chest pain (NCCP) is defined as recurring, angina-like, retrosternal chest pain of noncardiac origin. Although patients with NCCP have excellent long-term prognosis, most suffer persistently from their symptoms. Several pathophysiological mechanisms have been suggested, including gastroesophageal reflux disease (GERD), esophageal motility disorder, esophageal hypersensitivity, and psychological comorbidity. Among them, GERD is the most common cause of NCCP. Therefore, GERD should first be considered as the underlying cause of symptoms in patients with NCCP. Empirical proton pump inhibitor (PPI) treatment with a preferably double dose for more than 2 months could be cost-effective. PPI test can also be used for diagnosis of GERD-related NCCP, but it should be considered for patients with NCCP occurring at least weekly and its duration should be at least 2 weeks. However, upper endoscopy and esophageal pH monitoring are necessary when the diagnosis of GERD is uncertain. Esophageal impedance-pH monitoring could further improve the diagnostic yield. Patients with GERD-related NCCP should preferably be treated with a double dose PPI until symptoms remit (may require more than 2 months of therapy for optimal symptom control), followed by dose tapering to determine the lowest PPI dose that can control symptoms. However, treatment of patients with non-GERD-related NCCP is challenging. An empirical treatment of antidepressants could be considered. If there are specific esophageal motility disorders, smooth muscle relaxants or endoscopic treatment may be considered in selected cases. If none of these traditional treatments is effective, a psychology consultation for cognitive behavioral therapy should be considered.
Chest Pain/*diagnosis/etiology
;
Esophageal pH Monitoring
;
Gastroesophageal Reflux/complications/*diagnosis/drug therapy
;
Humans
;
Manometry
;
Proton Pump Inhibitors/therapeutic use
2.Clinical Characteristics of Gastroesophageal Reflux Diseases and Association with Helicobacter pylori Infection.
Byung Chang KIM ; Young Hoon YOON ; Hyun Soo JYUNG ; Jae Bock CHUNG ; Chae Yun CHON ; Sang In LEE ; Yong Chan LEE
The Korean Journal of Gastroenterology 2006;47(5):363-369
BACKGROUND/AIMS: The prevalence of gastroesophageal reflux disease (GERD) in Korea was believed to be low until now. Korea is now believed to be on the evolving stage of GERD in its' prevalence. The aims of this study were to evaluate the epidemiologic and clinicopathologic characteristics among the subgroups of GERD i.e. non-erosive GERD (NERD), erosive GERD (ERD) and Barrett's esophagus (BE), and the role of Helicobacter pylori (H. pylori) infection in the pathogenesis of GERD. METHODS: A total of 253 patients with typical symptoms of GERD who underwent EGD were enrolled from October 2002 to January 2004. Patients were grouped as NERD, ERD or BE based on the symptoms and endoscopic findings. BE was histologically confirmed if necessary. Various clinical parameters including the status of H. pylori infection were analyzed. RESULTS: Among 253 patients, 106 patients were classified as NERD while 116 and 31 patients were classified as ERD and BE group respectively. BE and ERD group showed no gender predilection while NERD showed female preponderance (2.31:1, p<0.05). NERD group were younger (49.57 y.o.) than BE (57.87 y.o.) and ERD (52.30 y.o.) group. About three quarters of the patients of erosive esophagitis were LA-A (74.2%) grade. This suggests the mild nature of erosive esophagitis in Korea. ERD showed significantly higher BMI (kg/m2) compared to NERD (p<0.05). Hiatal hernia was frequently associated with BE and ERD (p<0.05), but less frequently in NERD. Overall H. pylori positivity among GERD was significantly lower than the age and gender matched control group (p<0.05). CONCLUSIONS: Subgroups of GERD in Korea showed different epidemiologic and clinical characteristics. Lower rate of H. pylori infection among GERD group may reflect the protective role of H. pylori infection regarding GERD prevalence in Korea.
Aged
;
Barrett Esophagus/diagnosis/drug therapy/microbiology
;
Female
;
Gastroesophageal Reflux/diagnosis/drug therapy/*microbiology
;
Helicobacter Infections/*complications/drug therapy/epidemiology
;
*Helicobacter pylori
;
Humans
;
Korea/epidemiology
;
Male
;
Middle Aged
;
Prevalence
3.Clinical observation on treatment of reflux gastro-esophagitis by syndrome-differentiation depending therapy of TCM.
Xing-hong ZHAI ; Qi SHU ; Jin-mei DENG ; Chunhua WU ; Boxiang TANG ; Haiying AN ; Shengsheng ZHANG ; Wen LIU
Chinese Journal of Integrated Traditional and Western Medicine 2004;24(11):1014-1015
4.Updated Guidelines 2012 for Gastroesophageal Reflux Disease.
Hye Kyung JUNG ; Su Jin HONG ; Yunju JO ; Seong Woo JEON ; Yu Kyung CHO ; Kwang Jae LEE ; Joon Seong LEE ; Hyo Jin PARK ; Ein Soon SHIN ; Sun Hee LEE ; Sang Uk HAN
The Korean Journal of Gastroenterology 2012;60(4):195-218
In 2010, a Korean guideline for the management of gastroesophageal reflux disease (GERD) was made by the Korean Society of Neurogastroenterology and Motility, in which the definition and diagnosis of GERD were not included. The aim of this guideline was to update the clinical approach to the diagnosis and management of GERD in adult patients. This guideline was developed by the adaptation process of the ADAPTE framework. Twelve guidelines were retrieved from initial queries through the Appraisal of Guidelines for Research & Evaluation II process. Twenty-seven statements were made as a draft and revised by modified Delphi method. Finally, 24 consensus statements for the definition (n=4), diagnosis (n=7) and management (n=13) of GERD were developed. Multidisciplinary experts participated in the development of the guideline, and the external review of the guideline was conducted at the finalization phase.
Antacids/therapeutic use
;
Anti-Ulcer Agents/therapeutic use
;
Antidepressive Agents/therapeutic use
;
Barrett Esophagus/complications/diagnosis
;
Databases, Factual
;
Diet
;
Dose-Response Relationship, Drug
;
Drug Administration Schedule
;
Drug Therapy, Combination
;
Endoscopy, Digestive System
;
Esophageal pH Monitoring
;
Gastroesophageal Reflux/complications/*diagnosis/drug therapy
;
Histamine Antagonists/therapeutic use
;
Humans
;
Peptic Ulcer/complications/diagnosis
;
Proton Pump Inhibitors/therapeutic use
;
Stomach Neoplasms/complications/diagnosis
5.Clinical Features of Eosinophilic Bronchitis.
Jae Hak JOO ; Sang Joon PARK ; Sung Woo PARK ; June Hyuk LEE ; Do Jin KIM ; Soo Taek UH ; Yong Hoon KIM ; Choon Sik PARK
The Korean Journal of Internal Medicine 2002;17(1):31-37
BACKGROUND: Eosinophilic inflammation of the airway is usually associated with airway hyper-responsiveness in bronchial asthma. However, there is a small group of patients which has the eosinophilic inflammation in the bronchial tree with normal spirometry and no evidence of airway hyper-responsiveness, which was named eosinophilic bronchitis. The objectives of this study are 1) to investigate the incidence of eosinophilic bronchitis in the chronic cough syndrome and 2) to evaluate the clinical features and course of eosinophilic bronchitis. METHODS: We evaluated 92 patients who had persistent cough for 3 weeks or longer. In addition to routine diagnostic protocol, we performed differential cell count of sputum. Eosinophilic bronchitis was diagnosed when the patient had normal spirometric values, normal peak expiratory flow variability, no airway hyper-responsiveness and sputum eosinophilia (>3%). RESULTS: The causes of chronic cough were post-nasal drip in 33%, cough variant asthma in 16%, chronic bronchitis in 15% and eosinophilic bronchitis in 12% of the study subjects. Initial eosinophil percentage in the sputum of patients with eosinophilic bronchitis was 26.8+/-6.1% (3.8-63.7%). Treatment with inhaled steroid is related with a subjective improvement of cough severity and a significant decrease of sputum eosinophil percentage (from 29.1+/-8.3% to 7.4+/-3.3%). During the follow-up period, increase in sputum eosinophil percentage with aggravation of symptoms were found. CONCLUSION: Eosinophilic bronchitis is one of the important cause of chronics cough. Assessment of airway inflammation by sputum examination is important in investigating the cause of chronic cough. Cough in eosinophilic bronchitis is effectively controlled by inhaled corticosteroid, but may follow a chronic course.
Adult
;
Aged
;
Anti-Inflammatory Agents, Steroidal/therapeutic use
;
Asthma/complications/epidemiology
;
Bronchitis/*complications/diagnosis/drug therapy/epidemiology
;
Budesonide/therapeutic use
;
Chronic Disease
;
Cough/epidemiology/*etiology
;
Eosinophilia/*complications/diagnosis/drug therapy/epidemiology
;
Female
;
Gastroesophageal Reflux/complications/epidemiology
;
Human
;
Male
;
Middle Age
;
Respiratory Function Tests
;
Severity of Illness Index
;
Sputum/chemistry/immunology
6.Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea, 2013 Revised Edition.
Sang Gyun KIM ; Hye Kyung JUNG ; Hang Lak LEE ; Jae Young JANG ; Hyuk LEE ; Chan Gyoo KIM ; Woon Geon SHIN ; Ein Soon SHIN ; Yong Chan LEE
The Korean Journal of Gastroenterology 2013;62(1):3-26
Since the Korean College of Helicobacter and Upper Gastrointestinal Research has first developed the guideline for the diagnosis and treatment of Helicobacter pylori infection in 1998, the revised guideline was proposed in 2009 by the same group. Although the revised guideline was made by comprehensive review of previous articles and consensus of authoritative expert opinions, the evidence-based developmental process was not applied in the revision of the guideline. This new guideline has been revised especially in terms of changes in the indication and treatment of H. pylori infection in Korea, and developed by the adaptation process as evidence-based method; 6 guidelines were retrieved by systematic review and the Appraisal of Guidelines for Research and Evaluation (AGREE) II process, 21 statements were made with grading system and revised by modified Delphi method. After revision, 11 statements for the indication of test and treatment, 4 statements for the diagnosis and 4 statements for the treatment have been developed, respectively. The revised guideline has been reviewed by external experts before the official endorsement, and will be disseminated for usual clinical practice in Korea. Also, the scheduled update and revision of the guideline will be made periodically.
Amoxicillin/therapeutic use
;
Anti-Bacterial Agents/therapeutic use
;
Aspirin/therapeutic use
;
Bismuth/therapeutic use
;
Breath Tests
;
Clarithromycin/therapeutic use
;
Gastroesophageal Reflux/etiology
;
Gastroscopy
;
Helicobacter Infections/complications/*diagnosis/drug therapy
;
*Helicobacter pylori
;
Humans
;
Lymphoma, B-Cell, Marginal Zone/complications
;
Metaplasia/complications
;
Metronidazole/therapeutic use
;
Peptic Ulcer/complications/drug therapy
;
Proton Pump Inhibitors/therapeutic use
;
Republic of Korea
;
Stomach Neoplasms/complications/surgery
;
Tetracycline/therapeutic use
7.Clinicopathologic Analysis of Proton Pump Inhibitor-Responsive Esophageal Eosinophilia in Korean Patients.
Da Hyun JUNG ; Gak Won YUN ; Yoo Jin LEE ; Yunju JO ; Hyojin PARK
Gut and Liver 2016;10(1):37-41
BACKGROUND/AIMS: Proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE) is a newly recognized form of eosinophilic esophagitis (EoE) that responds to PPI therapy. It remains unclear whether PPI-REE represents a subphenotype of gastroesophageal reflux disease, a subphenotype of EoE, or its own distinct entity. The aim was to evaluate the clinicopathologic features of PPI-REE. METHODS: Six patients were diagnosed with PPI-REE based on symptoms, endoscopic abnormalities, esophageal eosinophilia with > or =15 eosinophils/high-power field, and a response to PPI treatment. Symptoms and endoscopic and pathological findings were evaluated. RESULTS: The median follow-up duration was 12 months. Presenting symptoms included dysphagia, heartburn, chest pain, foreign body sensation, acid reflux, and sore throat. All patients had typical endoscopic findings of EoE such as esophageal rings, linear furrows, nodularity, and whitish plaques. Three patients had a concomitant allergic disorder, and one had reflux esophagitis. Four patients exhibited elevated serum IgE, and five had positive skin prick tests. All patients experienced symptomatic resolution within 4 weeks and histologic resolution within 8 weeks after starting PPI therapy. There was no symptomatic recurrence. CONCLUSIONS: PPI therapy induced rapid resolution of symptoms and eosinophil counts in patients with PPI-REE. Large-scale studies with long-term follow-up are warranted.
Adult
;
Asian Continental Ancestry Group
;
Chest Pain/etiology
;
Deglutition Disorders/etiology
;
Diagnosis, Differential
;
Eosinophilic Esophagitis/complications/*drug therapy/*pathology
;
Esophagus/pathology
;
Female
;
Follow-Up Studies
;
Gastroesophageal Reflux/etiology
;
Heartburn/etiology
;
Humans
;
Male
;
Middle Aged
;
Pharyngitis/etiology
;
Phenotype
;
Proton Pump Inhibitors/*therapeutic use
;
Republic of Korea
;
Retrospective Studies
;
Sensation Disorders/etiology
;
Treatment Outcome
;
Young Adult